NDA 022526 · Sprout Pharms
Addyi
Flibanserin · Oral
NovelLast checked: Nov 20, 2026Latest source record: Dec 13, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2015
Aug 18, 2015
Approved uses
2
Original approval plus efficacy supplements
Registered trials
20
12 Phase 3, 0 recruiting
FAERS reports
2,007
106 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: HYPOTENSION and SYNCOPE IN CERTAIN SETTINGS Interaction with Alcohol The use of ADDYI and alcohol together close in time increases the risk of severe hypotension and syncope [see Warnings and Precautions (5.1) ]. Counsel patients to wait at least two hours after consuming one or two standard alcoholic drinks before taking ADDYI at bedtime or to skip their ADDYI dose if they have consumed three or more standard alcoholic drinks that evening. Contraindicated with Strong or Moderate CYP3A4 Inhibitors The concomitant use of ADDYI and moderate or strong CYP3A4 inhibitors increases flibanserin concentrations, which can cause severe hypotension and syncope [see Warnings and Precautions (5.2) ] . Therefore, the use of moderate or strong CYP3A4 inhibitors is contraindicated in patients taking ADDYI [see Contraindications (4) ] . Contraindicated in Patients with Hepatic Impairment The...
What it is approved for
From the label in effect Dec 22, 2025.
ADDYI is indicated for the treatment of women less than 65 years of age with acquired, generalized hypoactive sexual desire disorder (HSDD) as characterized by low sexual desire that causes marked distress or interpersonal difficulty and is not due to: • A co-existing medical or psychiatric condition, • Problems within the relationship, or • The effects of a medication or other drug substance. Acquired HSDD refers to HSDD that develops in a patient who previously had no problems with sexual desire. Generalized HSDD refers to HSDD that occurs regardless of the type of stimulation, situation or partner. Limitations of Use • ADDYI is not indicated in men. • ADDYI is not indicated to enhance sexual performance. ADDYI is indicated for the treatment of women less than 65 years of age with acquired, generalized hypoactive sexual desire disorder (HSDD) as characterized by low sexual desire that causes marked distress or interpersonal difficulty and is not due to ( 1 ): • A co-existing medical or psychiatric condition, • Problems within the relationship, or • The effects of a medication or other drug substance. Limitations of Use: • ADDYI is not indicated in men (1) • ADDYI is not indicated to enhance sexual performance. ( 1 )
Mechanism: The mechanism of action of ADDYI in the treatment of women less than 65 years of age with acquired, generalized HSDD as characterized by low sexual desire that causes marked distress or interpersonal difficulty (not due a co-existing medical or psychiatric condition, problems within the relationship, or the effects of a medication or other drug substance) is not known.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Dec 13, 2025 Supplement 13 · Efficacy · priority review LetterLabel
- Aug 18, 2015 Original approval · Type 1 - New Molecular Entity NovelLabelReviewOther
1 products under this application
- ADDYI · FLIBANSERIN 100MG · TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Flibanserin" as an intervention, any sponsor and status, largest first.
- A One-year Safety Study of Flibanserin to Treat Pre-Menopausal Women With Hypoactive Sexual Desire Disorder (HSDD).Pivotal-lookingTerminated
Sprout Pharmaceuticals, IncIndustry
NCT00441558 · 1,723 participants · Start Feb 2007 · Primary completion Aug 2009
Drug: Flibanserin · For: Sexual Dysfunctions, Psychological
Sites: Birmingham, Alabama; Huntsville, Alabama; Mobile, Alabama · 196 sites in all
- Uptitration Trial of Flibanserin Versus Placebo in Premenopausal Women With Hypoactive Sexual Desire DisorderPivotal-lookingCompleted
Sprout Pharmaceuticals, IncIndustry
NCT00360555 · 1,584 participants · Start Jul 2006 · Primary completion Mar 2008
Drug: flibanserin; flibanserin 50mg and 2 more · For: Sexual Dysfunctions, Psychological
Sites: Birmingham, Alabama; Mobile, Alabama; Phoenix, Arizona · 77 sites in all
- 6-mo. Min Eff Dose of Flibanserin: 25 v 50 mg Bid v 50 mg hs v Pbo in Younger Women in NAPivotal-lookingCompleted
Sprout Pharmaceuticals, IncIndustry
NCT00360243 · 1,385 participants · Start Jul 2006 · Primary completion Apr 2008
Drug: flibanserin; flibanserin and 2 more · For: Sexual Dysfunctions, Psychological
Sites: Huntsville, Alabama; Mobile, Alabama; Tucson, Arizona · 81 sites in all
- Fixed 100 mg Every Evening of Flibanserin vs Placebo in Premenopausal Women With Hypoactive Sexual Desire DisorderPivotal-lookingCompleted
Sprout Pharmaceuticals, IncIndustry
NCT00996164 · 1,090 participants · Start Oct 2009 · Primary completion Dec 2010
Drug: Flibanserin; Placebo · For: Sexual Dysfunctions, Psychological
Sites: Birmingham, Alabama; Huntsville, Alabama; Mobile, Alabama · 75 sites in all
- Flibanserin for the Treatment of Hypoactive Sexual Desire Disorder in Postmenopausal WomenPivotal-lookingCompleted
Sprout Pharmaceuticals, IncIndustry
NCT00996372 · 949 participants · Start Oct 2009 · Primary completion Mar 2011
Drug: flibanserin; placebo · For: Sexual Dysfunctions, Psychological
Sites: Birmingham, Alabama; Huntsville, Alabama; Mobile, Alabama · 75 sites in all
- Flibanserin Versus Placebo in Premenopausal Women With HSDDPivotal-lookingCompleted
Sprout Pharmaceuticals, IncIndustry
NCT00491829 · 945 participants · Start Jun 2007 · Primary completion Mar 2009
Drug: 50 mg qhs; 100 mg and 1 more · For: Sexual Dysfunctions, Psychological
Sites: Innsbruck, Austria; Vienna, Austria; Wörgl, Austria · 86 sites in all
- 24-week Placebo-controlled Trial of Flibanserin Once Daily in Premenopausal Women With Hypoactive Sexual Desire DisorderPivotal-lookingCompleted
Sprout Pharmaceuticals, IncIndustry
NCT00360529 · 880 participants · Start Jul 2006 · Primary completion Apr 2008
Drug: flibanserin · For: Sexual Dysfunctions, Psychological
Sites: Mobile, Alabama; South Birmingham, Alabama; Phoenix, Arizona · 54 sites in all
- Flibanserin Randomized Withdrawal Trial in Pre-menopausal WomenPivotal-lookingCompleted
Sprout Pharmaceuticals, IncIndustry
NCT00277914 · 749 participants · Start Jan 2006 · Primary completion Jul 2007
Drug: Flibanserin · For: Sexual Dysfunctions, Psychological
Sites: Birmingham, Alabama; Mobile, Alabama; Scottsdale, Arizona · 65 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective563
- dizziness332
- nausea199
- somnolence168
- product use in unapproved indication154
- fatigue142
- insomnia142
- headache130
- feeling abnormal101
- adverse drug reaction100
- malaise83
- product use issue63
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2015 | 1 |
| 2016 | 54 |
| 2017 | 20 |
| 2018 | 19 |
| 2019 | 28 |
| 2020 | 184 |
| 2021 | 327 |
| 2022 | 380 |
| 2023 | 364 |
| 2024 | 331 |
| 2025 | 261 |
| 2026 | 38 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Role of flibanserin in managing hypoactive sexual desire disorder in women: A systematic review and meta-analysis.
Kamrul-Hasan ABM, Hannan MA, Alam MS, et al. · Medicine (Baltimore) 2024 · Meta-Analysis, Systematic Review
- Female Sexual Desire, Arousal, and Orgasmic Dysfunctions: A Systematic Review and Meta-Analysis of Treatment Options.
Toledo RG, Winkelman WD, Reyes-Gonzalez D, et al. · J Minim Invasive Gynecol 2026 · Systematic Review, Meta-Analysis
- Next-day residual effects of flibanserin on simulated driving performance in premenopausal women.
Kay GG, Hochadel T, Sicard E, et al. · Hum Psychopharmacol 2017 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Systematic Review and Meta-analysis of Flibanserin's Effects and Adverse Events in Women with Hypoactive Sexual Desire Disorder.
Saadat SH, Kabir A, Rahmani K, et al. · Curr Drug Metab 2017 · Meta-Analysis, Systematic Review
- [Efficacy and safety of flibanserin "new female Viagra®?": Literature review].
Terrier C, Terrier JE · Prog Urol 2016 · Meta-Analysis, Systematic Review
- Flibanserin in Postmenopausal Women With Hypoactive Sexual Desire Disorder: Results of the PLUMERIA Study.
Portman DJ, Brown L, Yuan J, et al. · J Sex Med 2017 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
Sponsor: Sprout Pharms
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.